182 related articles for article (PubMed ID: 23745794)
1. Comparative analysis of MAPK and PI3K/AKT pathway activation and inhibition in human and canine melanoma.
Fowles JS; Denton CL; Gustafson DL
Vet Comp Oncol; 2015 Sep; 13(3):288-304. PubMed ID: 23745794
[TBL] [Abstract][Full Text] [Related]
2. Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells.
Gopal YN; Deng W; Woodman SE; Komurov K; Ram P; Smith PD; Davies MA
Cancer Res; 2010 Nov; 70(21):8736-47. PubMed ID: 20959481
[TBL] [Abstract][Full Text] [Related]
3. Exploration of genetic alterations in human endometrial cancer and melanoma: distinct tumorigenic pathways that share a frequent abnormal PI3K/AKT cascade.
Ogawa K; Sun C; Horii A
Oncol Rep; 2005 Dec; 14(6):1481-5. PubMed ID: 16273242
[TBL] [Abstract][Full Text] [Related]
4. Exon 15 BRAF mutations are uncommon in canine oral malignant melanomas.
Shelly S; Chien MB; Yip B; Kent MS; Theon AP; McCallan JL; London CA
Mamm Genome; 2005 Mar; 16(3):211-7. PubMed ID: 15834638
[TBL] [Abstract][Full Text] [Related]
5. The PI3K/Akt and mTOR/P70S6K signaling pathways in human uveal melanoma cells: interaction with B-Raf/ERK.
Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
Invest Ophthalmol Vis Sci; 2010 Jan; 51(1):421-9. PubMed ID: 19661225
[TBL] [Abstract][Full Text] [Related]
6. Analysis of KIT expression and KIT exon 11 mutations in canine oral malignant melanomas.
Murakami A; Mori T; Sakai H; Murakami M; Yanai T; Hoshino Y; Maruo K
Vet Comp Oncol; 2011 Sep; 9(3):219-24. PubMed ID: 21848624
[TBL] [Abstract][Full Text] [Related]
7. Dual inhibition of mitogen-activated protein kinase kinase and mammalian target of rapamycin in differentiated and anaplastic thyroid cancer.
Jin N; Jiang T; Rosen DM; Nelkin BD; Ball DW
J Clin Endocrinol Metab; 2009 Oct; 94(10):4107-12. PubMed ID: 19723757
[TBL] [Abstract][Full Text] [Related]
8. IQGAP1 is an oncogenic target in canine melanoma.
Lee BH; Neela PH; Kent MS; Zehnder AM
PLoS One; 2017; 12(4):e0176370. PubMed ID: 28445541
[TBL] [Abstract][Full Text] [Related]
9. Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas.
Manca A; Lissia A; Capone M; Ascierto PA; Botti G; Caracò C; Stanganelli I; Colombino M; Sini M; Cossu A; Palmieri G
J Transl Med; 2015 Jan; 13():37. PubMed ID: 25627962
[TBL] [Abstract][Full Text] [Related]
10. Effects of inhibitors of vascular endothelial growth factor receptor 2 and downstream pathways of receptor tyrosine kinases involving phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin or mitogen-activated protein kinase in canine hemangiosarcoma cell lines.
Adachi M; Hoshino Y; Izumi Y; Sakai H; Takagi S
Can J Vet Res; 2016 Jul; 80(3):209-16. PubMed ID: 27408334
[TBL] [Abstract][Full Text] [Related]
11. Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation.
Ghosh PM; Malik SN; Bedolla RG; Wang Y; Mikhailova M; Prihoda TJ; Troyer DA; Kreisberg JI
Endocr Relat Cancer; 2005 Mar; 12(1):119-34. PubMed ID: 15788644
[TBL] [Abstract][Full Text] [Related]
12. Constitutive activation of the ERK pathway in melanoma and skin melanocytes in Grey horses.
Jiang L; Campagne C; Sundström E; Sousa P; Imran S; Seltenhammer M; Pielberg G; Olsson MJ; Egidy G; Andersson L; Golovko A
BMC Cancer; 2014 Nov; 14():857. PubMed ID: 25413220
[TBL] [Abstract][Full Text] [Related]
13. Positive feedback loop between PI3K-Akt-mTORC1 signaling and the lipogenic pathway boosts Akt signaling: induction of the lipogenic pathway by a melanoma antigen.
Yamauchi Y; Furukawa K; Hamamura K; Furukawa K
Cancer Res; 2011 Jul; 71(14):4989-97. PubMed ID: 21632551
[TBL] [Abstract][Full Text] [Related]
14. The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition.
Jiang X; Zhou J; Giobbie-Hurder A; Wargo J; Hodi FS
Clin Cancer Res; 2013 Feb; 19(3):598-609. PubMed ID: 23095323
[TBL] [Abstract][Full Text] [Related]
15. Cross-Species Comparison of the Pan-RAF Inhibitor LY3009120's Anti-Tumor Effects in Equine, Canine, and Human Malignant Melanoma Cell Lines.
Gao Y; Packeiser EM; Wendt S; Sekora A; Cavalleri JV; Pratscher B; Alammar M; Hühns M; Brenig B; Junghanss C; Nolte I; Murua Escobar H
Genes (Basel); 2024 Feb; 15(2):. PubMed ID: 38397192
[TBL] [Abstract][Full Text] [Related]
16. Investigation of the effects of mTOR inhibitors rapamycin and everolimus in combination with carboplatin on canine malignant melanoma cells.
Bernard S; Poon AC; Tam PM; Mutsaers AJ
BMC Vet Res; 2021 Dec; 17(1):382. PubMed ID: 34895222
[TBL] [Abstract][Full Text] [Related]
17. Novel mechanisms and therapeutic approaches in melanoma: targeting the MAPK pathway.
Grimaldi AM; Simeone E; Festino L; Vanella V; Palla M; Ascierto PA
Discov Med; 2015 Jun; 19(107):455-61. PubMed ID: 26175403
[TBL] [Abstract][Full Text] [Related]
18. Dual inhibition of (V600E)BRAF and the PI3K/AKT/mTOR pathway cooperates to induce apoptosis in melanoma cells through a MEK-independent mechanism.
Sánchez-Hernández I; Baquero P; Calleros L; Chiloeches A
Cancer Lett; 2012 Jan; 314(2):244-55. PubMed ID: 22056813
[TBL] [Abstract][Full Text] [Related]
19. The MAPK pathway functions as a redundant survival signal that reinforces the PI3K cascade in c-Kit mutant melanoma.
Todd JR; Scurr LL; Becker TM; Kefford RF; Rizos H
Oncogene; 2014 Jan; 33(2):236-45. PubMed ID: 23246970
[TBL] [Abstract][Full Text] [Related]
20. Naturally Occurring Canine Melanoma as a Predictive Comparative Oncology Model for Human Mucosal and Other Triple Wild-Type Melanomas.
Hernandez B; Adissu HA; Wei BR; Michael HT; Merlino G; Simpson RM
Int J Mol Sci; 2018 Jan; 19(2):. PubMed ID: 29385676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
